Written and maintained by CASRAI Editorial Board
Published
On this page
CAPA in the pharmaceutical industry means corrective and preventive action: a quality-system process that investigates a problem, removes its cause so it does not recur (corrective action), and removes the cause of a problem that has not yet happened (preventive action). For drug manufacturers the expectation is set by ICH Q10, the FDA’s 2006 quality systems guidance and the investigation duties in 21 CFR Part 211.
This guide stays on the drug side of CAPA. It reads the three texts side by side, shows how ICH Q10 expects CAPA to operate across the product lifecycle, separates CAPA from root cause analysis, and explains how a CAPA system reaches suppliers and contract acceptors. For the medical device regulation, see the separate guide to CAPA under FDA device rules.
What is CAPA in the pharmaceutical industry?
ICH Q10 (Pharmaceutical Quality System, Step 4 version of 4 June 2008) states in section 3.2.2 that the pharmaceutical company should have a system for implementing corrective actions and preventive actions resulting from the investigation of complaints, product rejections, non-conformances, recalls, deviations, audits, regulatory inspections and findings, and trends from process performance and product quality monitoring. The same section says the investigation should follow a structured approach aimed at determining the root cause, and that the level of effort, formality and documentation should be commensurate with the level of risk, in line with ICH Q9.
The FDA’s guidance Quality Systems Approach to Pharmaceutical CGMP Regulations (September 2006, nonbinding) describes CAPA as a well-known CGMP concept that focuses on investigating, understanding and correcting discrepancies while attempting to prevent their recurrence. Its glossary defines CAPA as a systematic approach that includes actions needed to correct (correction), prevent recurrence (corrective action) and eliminate the cause of potential nonconforming product and other quality problems (preventive action), citing 21 CFR 820.100, the device regulation.
For a plain definition aimed at general research quality systems, the dictionary entry CAPA (corrective and preventive action) covers the term itself.
Definition and scope: where the regulatory text actually sits
A point that many vendor explainers blur: Part 211 itself does not use the word CAPA. What 21 CFR 211.192 does require is that any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications, be thoroughly investigated, whether or not the batch has already been distributed. The investigation must extend to other batches of the same drug product and to other drug products that may have been associated with the failure or discrepancy, and a written record must be made that includes the conclusions and follow-up. The CAPA vocabulary and the expectation of a systematic process come from ICH Q10 and the FDA’s quality systems guidance, which explain how a firm can meet the investigation and correction duties in a consistent way.
Complaints connect to the same duty. Under 21 CFR 211.198, written complaint-handling procedures must include review by the quality control unit of any complaint involving possible failure of a drug product to meet a specification, and a determination of whether an investigation under 211.192 is needed. Where no investigation is conducted, the record must state why none was found necessary and name the responsible person who decided that. Where one is conducted, the record must include the findings and follow-up.
The three concepts inside CAPA
The FDA guidance separates three concepts that are often run together under the one acronym:
- Remedial correction of an identified problem.
- Root cause analysis with corrective action, to understand the cause and potentially prevent recurrence. The guidance calls corrective action a reactive tool for system improvement, used to ensure that significant problems do not recur.
- Preventive action, to avert recurrence of a similar potential problem. The guidance describes this as being proactive.
ICH Q10 defines the second and third in its glossary, taking the wording from ISO 9000:2005: a corrective action eliminates the cause of a detected non-conformity or other undesirable situation and is taken to prevent recurrence, whereas a preventive action is taken to prevent occurrence and eliminates the cause of a potential non-conformity.
How CAPA is used in practice, according to the guidance
The FDA guidance sets out what a corrective action procedure should achieve. It should ensure that the need for action is evaluated relative to the consequences, that the root cause is investigated, that possible actions are determined, that the selected action is taken within a defined timeframe, and that its effectiveness is evaluated. It stresses that corrective actions taken must be documented, and notes that CGMP also requires this, with a reference to 211.192.
Inputs: what feeds a CAPA system
The two guidance texts name overlapping sources of information. Reading them together gives this list of inputs:
- complaints, product rejections, returns and nonconformance reports (both texts);
- deviations and recalls (ICH Q10);
- internal and external audits, and regulatory inspections and findings (both texts);
- trends from process performance and product quality monitoring (ICH Q10);
- data and risk assessment, and management review decisions (FDA guidance).
Preventive action in the FDA guidance
The FDA guidance gives examples of preventive action that are not product failures at all: succession planning, training, capturing institutional knowledge, and planning for personnel, policy and process changes. It expects preventive actions to be evaluated and recorded, and their effectiveness monitored. Preventive action in this reading is as much about the quality system and its people as about batch records.
Outputs: improvement and change
ICH Q10 section 3.2.2 says CAPA methodology should result in product and process improvements and enhanced product and process understanding. Section 3.2.3 connects CAPA outputs to change management, so that an action that alters a process, specification or procedure runs through a formal change system. The site’s guide to change control in pharma covers that next step, and CAPA process steps covers the workflow in generic terms.
Types of CAPA and related concepts
What are the different types of CAPA?
There are two actions in the name, and the FDA guidance adds a third element that precedes them. In its words the elements are correction (fixing the identified problem), corrective action (removing the cause of a detected problem so it does not recur) and preventive action (removing the cause of a potential problem). ICH Q10 recognises the same split through its glossary definitions. Neither text defines further named subtypes of CAPA, so labels such as “minor” or “critical” CAPA are a feature of individual company procedures, not of the regulatory texts. ICH Q10 asks only that the level of effort, formality and documentation be proportionate to risk.
What is the difference between CAPA and RCA?
Root cause analysis (RCA) is a step inside corrective action, not an alternative to it. ICH Q10 asks for a structured investigation with the objective of determining the root cause, and the FDA guidance lists root cause analysis together with corrective action as one of its three concepts. RCA answers why the problem happened. CAPA is the wider system that also decides what to do about it, does it within a defined timeframe, records it and checks that it worked. An investigation that names a cause but never leads to a tracked action and an effectiveness check has done the RCA and skipped the CAPA.
Where the trigger is a laboratory result, the investigation duty is usually met first through an OOS procedure; see out-of-specification (OOS) investigations for how these feed a CAPA.
CAPA across the product lifecycle (ICH Q10 Table II)
ICH Q10 does not treat CAPA as a manufacturing-floor tool only. Its Table II lists how CAPA applies at each lifecycle stage:
| Lifecycle stage | CAPA in ICH Q10 Table II |
|---|---|
| Pharmaceutical development | Product and process variability is explored; CAPA is incorporated into iterative design |
| Technology transfer | CAPA serves as feedback, feedforward and continual improvement |
| Commercial manufacturing | CAPA is used and the effectiveness of the actions is evaluated |
| Product discontinuation | CAPA continues after discontinuation, and the impact on product remaining on the market is considered |
The last row is the one most often missed: the obligation does not end when production stops, because product made earlier may still be in use.
Where CAPA matters for labs and supply decisions
What does CAPA stand for in supply chain?
The acronym does not change. In a pharmaceutical supply chain it is still corrective and preventive action, and none of the sources read here gives it another expansion. What changes is where the process reaches. ICH Q10 section 2.7 (outsourced activities and purchased materials) says the pharmaceutical company is ultimately responsible for outsourced activities and purchased materials. That includes assessing supplier suitability before selection (through audits, material evaluations and qualification), a written agreement for outsourced activities, monitoring and review of the contract acceptor’s or material’s quality, and identifying and implementing any needed improvements, along with monitoring incoming materials from approved sources through the agreed supply chain.
The FDA guidance points the same way: it calls for trend analysis of material acceptance and rejection to judge supplier performance, and periodic risk-based supplier audits. In practice a rejected lot of an incoming material is a CAPA input in the sense of the nonconformance and rejection sources listed above, and an improvement needed at a supplier is an action the company must follow through. A quality agreement is the written agreement that gives that follow-through a contractual footing.
For laboratories
Laboratories inside a drug manufacturer are covered by the same quality system, and 21 CFR 211.192 explicitly brings failures to meet specifications into the investigation duty. A lab discovering a recurring cause, such as a procedure that analysts interpret differently, has a corrective action question. A lab that sees a change coming, such as a new instrument or a staffing transition, has a preventive action question of the kind the FDA guidance describes through succession planning and training.
Common misunderstandings
- “CAPA is a section of Part 211.” The word does not appear in Part 211. The duties come from provisions such as 211.192 and 211.198, with the CAPA concept set out in ICH Q10 and the FDA guidance.
- “The FDA guidance is binding.” The 2006 guidance is nonbinding; the investigation requirements in the regulation are binding.
- “CAPA is only reactive.” Preventive action is half of the name and the FDA guidance gives proactive examples such as training and knowledge capture.
- “Closing the actions closes the CAPA.” Both texts expect effectiveness to be evaluated, not only completion.
- “Every event needs the same depth.” ICH Q10 ties the level of effort, formality and documentation to risk.
- “Device and drug CAPA are the same rule.” The FDA guidance borrows its glossary wording from the device regulation, 21 CFR 820.100, but the drug-side duties discussed here sit in Part 211 and ICH Q10.
Frequently asked questions
What is CAPA in the pharmaceutical industry?
It is corrective and preventive action, the quality-system process described in ICH Q10 section 3.2.2 for acting on complaints, rejections, deviations, audits and trends, with the investigation depth proportionate to risk.
What are different types of CAPA?
The FDA’s 2006 guidance distinguishes correction, corrective action and preventive action. Neither it nor ICH Q10 defines further regulatory subtypes; any severity tiers belong to a company’s own procedure.
What is the difference between CAPA and RCA?
RCA is the investigation step that identifies why a problem occurred. CAPA includes it and also covers selecting actions, completing them within a defined timeframe, documenting them and evaluating effectiveness.
What does CAPA stand for in supply chain?
The same thing: corrective and preventive action. In supply chains it applies through ICH Q10 section 2.7, which makes the company ultimately responsible for outsourced activities and purchased materials, including monitoring and improvement.
Does 21 CFR Part 211 require CAPA?
Part 211 does not use the term. Section 211.192 requires thorough investigation of unexplained discrepancies and specification failures, extending to other batches and products, with a written record of conclusions and follow-up.
Sources
- ICH: Q10 Pharmaceutical Quality System (Step 4, 4 June 2008), checked 2026-11-19
- FDA: Guidance for Industry, Quality Systems Approach to Pharmaceutical CGMP Regulations (September 2006), checked 2026-11-19
- Legal Information Institute (eCFR text): 21 CFR 211.192, Production record review, checked 2026-11-19
- Legal Information Institute (eCFR text): 21 CFR 211.198, Complaint files, checked 2026-11-19
Data: Investigation and follow-up duties for drug-product problems: 21 CFR 211.192, 211.198, ICH Q10 and FDA 2006 guidance
Side-by-side compilation of what four official texts say about when a problem must be investigated, how far the investigation extends, and what must be recorded or evaluated. Compiled from the CFR text of 21 CFR 211.192 and 211.198, ICH Q10 (Step 4, 2008) and the FDA guidance Quality Systems Approach to Pharmaceutical CGMP Regulations (2006).
Period covered: 2006/2008. Coverage: United States; international (ICH).
| Source | What triggers the investigation or action | Scope or depth | Record or follow-up expectation |
|---|---|---|---|
| 21 CFR 211.192 (binding regulation) | Any unexplained discrepancy, or failure of a batch or any of its components to meet specifications | Thorough investigation whether or not the batch is distributed; extends to other batches of the same product and other products that may be associated | Written record of the investigation, including conclusions and follow-up |
| 21 CFR 211.198 (binding regulation) | Complaints, including those involving possible failure to meet a specification | Quality control unit reviews and decides whether an investigation under 211.192 is needed | Complaint record; findings and follow-up if investigated, or the reason and the responsible person's name if not |
| ICH Q10 section 3.2.2 (guideline) | Complaints, rejections, non-conformances, recalls, deviations, audits, inspections and findings, and monitoring trends | Structured approach to determine root cause; effort, formality and documentation commensurate with risk (ICH Q9) | Should result in product and process improvements and enhanced understanding; outputs link to change management (3.2.3) |
| FDA guidance 2006, section on CAPA (nonbinding) | Nonconformance reports, rejections, returns, complaints, audits, data and risk assessment, management review decisions | Evaluate need for action relative to consequences; investigate root cause; take action within a defined timeframe | Document actions taken; evaluate effectiveness; preventive actions also evaluated, recorded and monitored |
| ICH Q10 section 2.7 (guideline) | Outsourced activities and purchased materials | Company ultimately responsible; supplier assessment before selection and monitoring and review afterwards | Written agreement; identify and implement needed improvements |
Sources
- ICH Q10 Pharmaceutical Quality System (accessed 2026-11-19)
- FDA Quality Systems Approach to Pharmaceutical CGMP Regulations (accessed 2026-11-19)
- 21 CFR 211.192 (accessed 2026-11-19)
- 21 CFR 211.198 (accessed 2026-11-19)
Compiled by CASRAI from the sources above. Free to reuse under CC BY 4.0 with attribution.







